<DOC>
	<DOCNO>NCT00826020</DOCNO>
	<brief_summary>The purpose study determine establish parenteral nutrition ( PN ) associate liver disease reverse progression halt use parenteral fat emulsion prepare fish oil measure normalization serum level hepatic enzymes bilirubin .</brief_summary>
	<brief_title>Evaluation Omegaven™ Parenteral Nutrition Patients With TPN-Induced Cholestasis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Patients must enrol Intestinal Rehabilitation Program University Nebraska Medical Center , AND : Be unable meet nutritional need solely enteral nutrition expect require PN least another 30 day Have clinical evidence parenteral nutrition associate liver disease ( PNALD ) define direct bilirubin 2 mg/dl . A liver biopsy desirable necessary treatment Signed patient inform consent Parent guardian child unwilling provide consent assent Inability unwillingness part parent/guardian child follow clinical recommendation Intestinal Rehabilitation Program Allergies clinical condition preclude safe use Omegaven™</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>PN</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>fat emulsion</keyword>
	<keyword>omega-6 fatty acid</keyword>
	<keyword>liver disease</keyword>
	<keyword>fatty acid deficiency</keyword>
</DOC>